Verici Dx plc (AIM: VRCI), a precision diagnostics company developing advanced clinical tests for organ transplant patients, has announced it will present and exhibit at the Mello2026 investor conference on Tuesday 17 November at The Clayton Hotel & Conference Centre, Chiswick High Road, London. Chief Executive Sara Barrington is scheduled to present twice during the day, at 12:25pm and 16:45pm, covering company strategy and its recently completed fundraise. The company has confirmed that no new information will be disclosed at the event, with presentation materials to be made available on the Verici Dx investor relations website.

Key Points

  • Verici Dx plc (AIM: VRCI) is an AIM-listed precision diagnostics developer focused on organ transplant care
  • CEO Sara Barrington will present at Mello2026 on 17 November 2026 at 12:25pm and 16:45pm at The Clayton Hotel, Chiswick, London
  • Management anticipates the recent fundraise will provide sufficient runway to reach cash-flow breakeven by the end of 2027
  • Investors should watch for the presentation PDF, which will be published at vericidx.com/investors/ following the event

Verici Dx Presents Transplant Diagnostics Strategy and Fundraise Update at Mello2026

Verici Dx plc will participate in the Mello2026 investor event, one of the UK's prominent retail and institutional investor conferences. CEO Sara Barrington will deliver two presentations on 17 November, providing attendees with an overview of the company's business model and strategic direction. The sessions will also address Verici Dx's recently completed fundraise, which the announcement states management anticipates will provide sufficient runway to achieve cash-flow breakeven by the end of 2027. The company has explicitly confirmed that no new material information will be disclosed at the event beyond what has previously been announced to the market.

Tutivia™ Post-Kidney Transplant Test Anchors Verici Dx's Commercial Pipeline

Verici Dx operates at the intersection of laboratory science and artificial intelligence, developing proprietary transcriptomic tests designed to assist clinicians in managing transplant patients. The company's lead commercially available product, Tutivia™, is a post-kidney transplant test focused on the early detection of acute rejection. The announcement states the company's tests are validated across inclusive, real-world patient populations to ensure clinical reliability. Verici Dx is headquartered in Cardiff in the UK and maintains a US presence in Franklin, Tennessee, reflecting its ambition to serve transplant patient populations in both markets.

Cash-Flow Breakeven Target of End-2027 Remains a Key Milestone for VRCI Investors

The reference to the recent successful fundraise and management's expectation of achieving cash-flow breakeven by the end of 2027 is likely to be a focal point for investors attending Mello2026. For an early-stage diagnostics company on AIM, runway visibility is a critical consideration, and the announcement signals that management regards the fundraise as sufficient to reach that operational milestone. The company did not disclose the size of the fundraise in this announcement. Investors may be watching for further clinical and commercial updates in the period between now and that target date, particularly regarding the adoption of Tutivia™.

Presentation Materials to Be Published on Verici Dx Investor Relations Website

Following the Mello2026 event, Verici Dx has confirmed a PDF of the CEO's presentation will be made publicly available via the company's investor relations page at vericidx.com/investors/, ensuring equal access to information for shareholders unable to attend in person. Singer Capital Markets acts as the company's Nominated Adviser and Joint Broker, with Oberon Capital serving as Joint Broker, and Walbrook PR handling media and investor relations. Investors interested in attending Mello2026 in person can find further details and tickets at melloevents.com/mellolondon2026.